Tony Keating
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Tony Keating
Non-Executive Director / NeuroScientific Biopharmaceuticals
Dr Tony Keating is an experienced entrepreneur and chief executive with over 10 years of experience in commercialising technology.
Dr Keating was the co-founder, chief executive and managing director of ResApp Health which he led from a startup to a $180M acquisition by Pfizer in 2022. He then became vice president at Pfizer, where he led the integration of ResApp's business into Pfizer. Prior to co-founding ResApp, Dr Keating was a director of commercial engagement at UniQuest where he led commercialisation of science-based technologies which included identification, development and funding of opportunities, as well as sourcing and negotiating transactions with investors and strategic partners.
Dr Keating holds a Doctor of Philosophy from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.
Dr Keating was the co-founder, chief executive and managing director of ResApp Health which he led from a startup to a $180M acquisition by Pfizer in 2022. He then became vice president at Pfizer, where he led the integration of ResApp's business into Pfizer. Prior to co-founding ResApp, Dr Keating was a director of commercial engagement at UniQuest where he led commercialisation of science-based technologies which included identification, development and funding of opportunities, as well as sourcing and negotiating transactions with investors and strategic partners.
Dr Keating holds a Doctor of Philosophy from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 16th | PharmAust | 331% | 61% |
| 91st | Botanix Pharmaceuticals | 100% | 43% |
| 1434th | NeuroScientific Biopharmaceuticals | -48% | -25% |
| 1612th | Nuheara | -60% | -44% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 121st |  | NeuroScientific Biopharmaceuticals | $5.0m |
| 128th |  | PharmAust | $3.8m |
| 129th | | ResApp Health | $3.8m |
| 131st | | Nuheara | $3.8m |
| 132nd | | Botanix Pharmaceuticals | $3.8m |
200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
| NEWS: Tagged in Board Moves December 5, 2023 | 05 Dec 2023 |
| NEW ROLE: Non-Executive Director, NeuroScientific Biopharmaceuticals | 05 Dec 2023 |
| NEWS: Tagged in Pfizer tacks $80m onto ResApp offer | 14 Jun 2022 |
| NEWS: Tagged in Pfizer makes $100m bid for ResApp | 11 Apr 2022 |
| REMUNERATION UPDATE: Co-Founder, Chief Executive, Managing Director, ResApp Health | 02 Nov 2020 |
| REMUNERATION UPDATE: Co-Founder, Chief Executive, Managing Director, ResApp Health | 24 Aug 2020 |
| REMUNERATION UPDATE: Co-Founder, Chief Executive, Managing Director, ResApp Health | 30 Jun 2020 |
